Search

Syncona Ltd

Closed

99.2 -1.2

Overview

Share price change

24h

Current

Min

98.1

Max

100.2

Key metrics

By Trading Economics

Income

-68M

Sales

44M

Profit margin

-153.576

Employees

1,215

EBITDA

-49M

Dividends

By Dow Jones

Next Earnings

13 Nov 2025

Market Stats

By TradingEconomics

Market Cap

614M

Previous open

100.4

Previous close

99.2

Syncona Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

7 Nov 2025, 21:06 UTC

Major Market Movers

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 Nov 2025, 18:10 UTC

Earnings

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 Nov 2025, 13:10 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 Nov 2025, 12:00 UTC

Earnings

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 Nov 2025, 10:30 UTC

Earnings

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 Nov 2025, 03:50 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 Nov 2025, 03:41 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 Nov 2025, 03:07 UTC

Acquisitions, Mergers, Takeovers

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 Nov 2025, 22:36 UTC

Earnings

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 Nov 2025, 22:22 UTC

Earnings

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 Nov 2025, 22:03 UTC

Earnings

Constellation Software 3Q Rev $2.95B >CSU.T

7 Nov 2025, 22:03 UTC

Earnings

Constellation Software 3Q Net $210M >CSU.T

7 Nov 2025, 22:03 UTC

Earnings

Constellation Software 3Q EPS $9.89 >CSU.T

7 Nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7 Nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7 Nov 2025, 20:59 UTC

Earnings

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 Nov 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 Nov 2025, 20:22 UTC

Earnings

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 Nov 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7 Nov 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7 Nov 2025, 19:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 Nov 2025, 19:17 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 Nov 2025, 19:09 UTC

Earnings

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 Nov 2025, 19:08 UTC

Earnings

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 Nov 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 Nov 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 Nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

Syncona Ltd Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Syncona Ltd

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
help-icon Live chat